V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160017234 | 160008564 | 1.61 | 87.8 | Palliative (P) | 2019-03-19 | 2019-03-20 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101628809 |
| 160017235 | 160008565 | 1.54 | 70.5 | Neo-adjuvant (N) | 2016-07-11 | 2016-07-12 | Carboplatin AUC 2 - 5 | 02 | null | CARBOPLATIN | 100370884 |
| 160017237 | 160008566 | 1.74 | 85.1 | Adjuvant (A) | 2018-12-07 | 2018-12-19 | CAPECITABINE + OXALIPLATIN | 02 | N | IFOSFAMIDE | 101592397 |
| 160017238 | 160008567 | null | null | Curative (C) | 2020-07-24 | 2020-07-26 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101691571 |
| 160017239 | 160008568 | 1.71 | 93.4 | Palliative (P) | 2014-01-15 | 2014-01-23 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101452508 |
| 160017242 | 160008569 | 1.8 | 100 | Palliative (P) | 2019-03-30 | 2019-04-07 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100044961 |
| 160017244 | 160008570 | 1.7 | 58.5 | Palliative (P) | 2018-07-23 | 2018-07-29 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100120291 |
| 160017245 | 160008571 | 1.62 | 77 | Palliative (P) | 2019-04-09 | 2019-04-16 | Doxorubicin + Olaratumab | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100445502 |
| 160017246 | 160008572 | 1.75 | 72.5 | Palliative (P) | 2017-12-07 | 2017-12-07 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | TRIAL UNSPECIFIED | 100598433 |
| 160017247 | 160008573 | 1.79 | 102 | Palliative (P) | null | 2019-10-31 | Liposomal Doxorubicin (Caelyx) | N | N | BEP | 100922074 |
| 160017251 | 160008574 | 1.66 | 74 | Palliative (P) | 2017-04-16 | 2017-04-16 | DACARBAZINE + DOXORUBICIN | N | 2 | DOXORUBICIN + IFOSFAMIDE | 101434073 |
| 160017253 | 160008575 | 1.7 | 70 | Adjuvant (A) | 2019-10-31 | 2019-11-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100091582 |
| 160017255 | 160008576 | 1.65 | 65 | null | 2017-04-11 | 2017-05-08 | Doxorubicin + Ifosfamide | N | N | EW EUROEWING 2012 ARM B VDC | 100161502 |
| 160017256 | 160008577 | 0 | 0 | Palliative (P) | null | 2019-03-12 | Carboplatin + Paclitaxel (3 weekly) | 02 | Y | CARBOPLATIN + PACLITAXEL | 101273599 |
| 160017257 | 160008578 | 1.62 | 54 | Not known (9) | 2018-09-15 | 2018-10-18 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100397247 |
| 160017258 | 160008579 | 1.73 | 104.7 | Neo-adjuvant (N) | 2019-05-06 | 2019-06-19 | EW EuroEwing 2012 Arm B VDC | 02 | N | BEP | 100638043 |
| 160017260 | 160008580 | 1.76 | 78 | Palliative (P) | 2019-12-19 | 2020-01-03 | Ifosfamide + Liposomal Doxorubicin | 02 | N | CARBOPLATIN + ETOPOSIDE | 100969350 |
| 160017262 | 160008581 | 1.75 | 66 | Curative (C) | 2017-07-12 | 2017-07-21 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100141709 |
| 160017264 | 160008582 | 1.75 | 55.7 | null | 2016-10-01 | 2016-10-08 | DOXORUBICIN | 02 | null | DOXORUBICIN | 101395326 |
| 160017266 | 160008583 | 1.79 | 56.2 | Palliative (P) | 2020-01-01 | 2020-01-01 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | CARBOPLATIN + PACLITAXEL | 100428702 |
| 160017267 | 160008584 | 1.69 | 72 | Curative (C) | 2019-10-25 | 2019-11-11 | Bevacizumab+Carbo+Gemcitabine | 02 | N | NOT MATCHED | 100926049 |
| 160017273 | 160008585 | 1.76 | 58.2 | Palliative (P) | 2017-08-11 | 2017-08-19 | Bevacizumab+Carbo+Pacliaxel | N | N | DOXORUBICIN | 100423693 |
| 160017276 | 160008586 | 1.82 | 77 | null | 2017-10-14 | 2017-10-19 | Liposomal Doxorubicin (Caelyx) | 02 | null | PACLITAXEL | 100469645 |
| 160017277 | 160008587 | 1.75 | 85.8 | Curative (C) | 2017-10-18 | 2017-10-20 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100030899 |
| 160017278 | 160008588 | 1.68 | 87.2 | null | null | null | Trial Unspecified | 02 | N | DOXORUBICIN | 101343203 |
| 160017282 | 160008589 | 1.49 | 102 | Palliative (P) | 2020-09-30 | 2020-10-27 | Rituximab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100736700 |
| 160017284 | 160008590 | 1.82 | 80.4 | Adjuvant (A) | 2017-11-07 | 2017-11-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101594948 |
| 160017286 | 160008591 | 1.74 | 90.7 | Neo-adjuvant (N) | 2018-02-04 | 2018-02-04 | null | 02 | N | CARBOPLATIN | 100416736 |
| 160017287 | 160008592 | 1.8 | 69 | Neo-adjuvant (N) | 2016-01-26 | 2016-02-01 | EW EuroEwing 2012 Arm B VDC | null | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 101651506 |
| 160017288 | 160008593 | 1.68 | 78.1 | Palliative (P) | 2018-11-12 | 2018-11-23 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN | 100003501 |
| 160017290 | 160008595 | 1.67 | 44.4 | Curative (C) | 2016-11-29 | 2016-11-29 | ICON8B TRIAL | N | N | CARBOPLATIN + PACLITAXEL | 101351572 |
| 160017291 | 160008596 | 1.59 | 86 | Palliative (P) | 2019-11-18 | 2019-12-06 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101414212 |
| 160017292 | 160008597 | 0 | 93.5 | Curative (C) | 2019-01-11 | 2019-01-20 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100607548 |
| 160017293 | 160008598 | 1.71 | 81.9 | Adjuvant (A) | 2018-11-03 | 2018-11-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100156394 |
| 160017297 | 160008599 | 1.66 | 97.65 | Neo-adjuvant (N) | 2018-12-24 | 2018-12-25 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101018565 |
| 160017298 | 160008600 | 1.71 | 114 | Palliative (P) | 2018-12-22 | 2019-01-11 | Doxorubicin + Olaratumab | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101191782 |
| 160017299 | 160008601 | null | null | null | 2016-11-10 | 2016-11-12 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100029304 |
| 160017306 | 160008602 | 1.75 | 61 | Palliative (P) | 2016-09-16 | 2016-09-21 | MELPHALAN | 02 | N | TRIAL UNSPECIFIED | 101549374 |
| 160017309 | 160008603 | 1.86 | 62.8 | null | 2016-12-11 | 2016-12-12 | CARBOPLATIN + PACLITAXEL | N | N | PACLITAXEL | 100668487 |
| 160017310 | 160008604 | 1.72 | 73.2 | Curative (C) | 2017-10-03 | 2017-10-03 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101185594 |
| 160017311 | 160008605 | 1.75 | 64 | Palliative (P) | 2019-05-28 | 2019-06-04 | Doxorubicin + Ifosfamide | 01 | N | BORTEZOMIB | 100104842 |
| 160017314 | 160008606 | 1.76 | 117.1 | Palliative (P) | 2017-07-29 | 2017-08-10 | Paclitaxel 80mg/m2 day 1 8 15 | 02 | N | PACLITAXEL | 101633755 |
| 160017316 | 160008607 | 1.82 | 52 | 03 | 2019-04-09 | 2019-04-09 | Cisplatin + Pemetrexed | 02 | N | ECX | 101690467 |
| 160017317 | 160008608 | 1.72 | 65.5 | Curative (C) | 2019-12-20 | 2019-12-24 | Doxorubicin + Olaratumab | 02 | N | NB HRNBL-1 COJEC IND COURSE B | 101618593 |
| 160017318 | 160008609 | 0 | 93.5 | Curative (C) | 2019-01-04 | 2019-01-05 | Doxorubicin + Ifosfamide | null | N | VINBLASTINE | 100679489 |
| 160017319 | 160008610 | null | null | Palliative (P) | null | 2017-11-22 | Doxorubicin + Ifosfamide | 02 | null | VINORELBINE | 100721299 |
| 160017320 | 160008611 | null | 62.4 | Palliative (P) | 2018-11-24 | 2018-11-26 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101022596 |
| 160017321 | 160008612 | 1.81 | 120 | Not known (9) | 2016-01-24 | 2016-02-03 | Pemetrexed | N | N | TRIAL UNSPECIFIED | 101584698 |
| 160017323 | 160008613 | 1.74 | 100 | Palliative (P) | null | 2016-11-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101178515 |
| 160017328 | 160008614 | 1.86 | 77 | null | 2019-02-23 | 2019-02-23 | STS Rhabdomyosarcoma RMS 2005 IVA | null | null | GEMCARBO | 101659424 |